NASDAQ:ZLAB

Zai Lab News Headlines

$132.63
-0.25 (-0.19 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$130.14
Now: $132.63
$134.31
50-Day Range
$125.11
MA: $140.97
$175.36
52-Week Range
$57.13
Now: $132.63
$193.54
Volume353,629 shs
Average Volume421,993 shs
Market Capitalization$11.75 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Headlines

Zai Lab (NASDAQ ZLAB) News Headlines Today

SourceHeadline
Zai Lab (ZLAB) Chairwoman & CEO Ying Du Sold $14.2 million of SharesZai Lab (ZLAB) Chairwoman & CEO Ying Du Sold $14.2 million of Shares
finance.yahoo.com - April 8 at 12:23 AM
Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $2,948,637.12 in StockZai Lab Limited (NASDAQ:ZLAB) CEO Sells $2,948,637.12 in Stock
americanbankingnews.com - April 7 at 10:46 PM
Insider Selling: Zai Lab Limited (NASDAQ:ZLAB) CEO Sells 50,784 Shares of StockInsider Selling: Zai Lab Limited (NASDAQ:ZLAB) CEO Sells 50,784 Shares of Stock
americanbankingnews.com - April 7 at 10:46 PM
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $127.69Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $127.69
americanbankingnews.com - April 7 at 11:00 AM
Kai-Xian Chen Sells 4,302 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockKai-Xian Chen Sells 4,302 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock
americanbankingnews.com - March 30 at 10:54 PM
First Week of ZLAB May 21st Options TradingFirst Week of ZLAB May 21st Options Trading
nasdaq.com - March 22 at 2:01 PM
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
finance.yahoo.com - March 20 at 8:21 AM
Zai Lab is Now Oversold (ZLAB)Zai Lab is Now Oversold (ZLAB)
nasdaq.com - March 8 at 12:23 PM
Why Amgens $1.9 Billion Takeover Might Only Whet Its Appetite In 2021Why Amgen's $1.9 Billion Takeover Might Only Whet Its Appetite In 2021
finance.yahoo.com - March 4 at 1:25 PM
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Updateargenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
benzinga.com - March 4 at 1:59 AM
Analysts Are More Bearish On Zai Lab Limited (NASDAQ:ZLAB) Than They Used To BeAnalysts Are More Bearish On Zai Lab Limited (NASDAQ:ZLAB) Than They Used To Be
finance.yahoo.com - March 3 at 10:25 AM
Zai Lab Reaches Analyst Target PriceZai Lab Reaches Analyst Target Price
nasdaq.com - March 2 at 1:09 PM
Zai Lab Limited 2020 Q4 - Results - Earnings Call PresentationZai Lab Limited 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 1 at 4:32 PM
Zai Lab Announces Financial Results for Second-half and Full-year 2020Zai Lab Announces Financial Results for Second-half and Full-year 2020
finance.yahoo.com - March 1 at 9:48 AM
Zai Lab earnings: heres what to expectZai Lab earnings: here's what to expect
markets.businessinsider.com - February 28 at 11:25 PM
ZLAB Mar 2021 165.000 callZLAB Mar 2021 165.000 call
uk.finance.yahoo.com - February 19 at 6:38 PM
Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
finance.yahoo.com - February 18 at 9:26 AM
ZLAB December 17th Options Begin TradingZLAB December 17th Options Begin Trading
nasdaq.com - January 19 at 6:13 PM
The ZLAB Paradox: Analysts Bullish But Forecast -23.94% FallThe ZLAB Paradox: Analysts Bullish But Forecast -23.94% Fall
nasdaq.com - January 11 at 9:13 AM
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater Chinaargenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
finance.yahoo.com - January 6 at 6:29 PM
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug ListZai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
finance.yahoo.com - December 28 at 11:55 PM
Zai Lab Collaborates With Cullinan Oncology On CLN-081Zai Lab Collaborates With Cullinan Oncology On CLN-081
nasdaq.com - December 28 at 8:54 AM
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast CancerZai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
finance.yahoo.com - December 16 at 10:08 PM
The ZLAB Paradox: Analysts Bullish But Forecast -1.45% FallThe ZLAB Paradox: Analysts Bullish But Forecast -1.45% Fall
nasdaq.com - December 7 at 4:48 PM
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, OncologyZai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
finance.yahoo.com - December 1 at 5:53 PM
Zai Lab Limited - American Depositary SharesZai Lab Limited - American Depositary Shares
benzinga.com - November 28 at 10:57 PM
ZLAB Nov 2020 75.000 putZLAB Nov 2020 75.000 put
uk.finance.yahoo.com - November 24 at 9:59 AM
ZLAB Nov 2020 80.000 putZLAB Nov 2020 80.000 put
uk.finance.yahoo.com - November 23 at 6:29 PM
Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial CancerZai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer
finance.yahoo.com - October 29 at 7:50 AM
Zai Lab Limited's (NASDAQ:ZLAB) Path To ProfitabilityZai Lab Limited's (NASDAQ:ZLAB) Path To Profitability
finance.yahoo.com - October 28 at 7:38 PM
Zai Lab Announces Upcoming Presentations in November Investor ConferencesZai Lab Announces Upcoming Presentations in November Investor Conferences
finance.yahoo.com - October 28 at 9:38 AM
Zai Lab Ltd. Reg. Shares (ADRs) (1ZL.SG)Zai Lab Ltd. Reg. Shares (ADRs) (1ZL.SG)
ca.finance.yahoo.com - October 16 at 3:01 PM
Zai Lab Limited (1ZL.F)Zai Lab Limited (1ZL.F)
in.finance.yahoo.com - October 13 at 1:21 PM
The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOsThe Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs
benzinga.com - October 9 at 7:22 AM
Zai Lab commences study in China testing margetuximab in stomach cancerZai Lab commences study in China testing margetuximab in stomach cancer
seekingalpha.com - October 6 at 9:25 AM
Zai Lab commences late-stage study of retifanlimab in lung cancerZai Lab commences late-stage study of retifanlimab in lung cancer
seekingalpha.com - October 5 at 1:32 PM
Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLCZai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC
markets.businessinsider.com - October 5 at 8:31 AM
Zai Lab Announces Closing of Hong Kong Secondary ListingZai Lab Announces Closing of Hong Kong Secondary Listing
marketwatch.com - September 28 at 12:16 PM
Zai Lab prices Hong Kong listing at HK$562Zai Lab prices Hong Kong listing at HK$562
seekingalpha.com - September 22 at 8:53 AM
ZTO Express Raises $1.27 Billion in Hong Kong ListingZTO Express Raises $1.27 Billion in Hong Kong Listing
finance.yahoo.com - September 22 at 8:53 AM
Zai Lab Announces Pricing of Hong Kong Secondary ListingZai Lab Announces Pricing of Hong Kong Secondary Listing
finance.yahoo.com - September 22 at 8:53 AM
Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPOWeek In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO
seekingalpha.com - September 21 at 5:45 PM
Zai Labs niraparib shows PFS benefit compared to placeboZai Lab's niraparib shows PFS benefit compared to placebo
seekingalpha.com - September 21 at 5:45 PM
Zai Lab niraparib shows PFS benefit, compared to placeboZai Lab' niraparib shows PFS benefit, compared to placebo
seekingalpha.com - September 21 at 12:44 PM
Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancerPhase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
finance.yahoo.com - September 19 at 8:46 AM
Zai Lab Launches Hong Kong Secondary ListingZai Lab Launches Hong Kong Secondary Listing
finance.yahoo.com - September 16 at 8:20 AM
Zai Labs Zejula OKd in China for first-line ovarian cancerZai Lab's Zejula OK'd in China for first-line ovarian cancer
seekingalpha.com - September 10 at 10:37 PM
Zai Labs Zeluja OKd in China for first-line maintenance treatment of ovarian cancerZai Lab's Zeluja OK'd in China for first-line maintenance treatment of ovarian cancer
seekingalpha.com - September 10 at 12:35 PM
Can You Imagine How Jubilant Zai Labs (NASDAQ:ZLAB) Shareholders Feel About Its 132% Share Price Gain?Can You Imagine How Jubilant Zai Lab's (NASDAQ:ZLAB) Shareholders Feel About Its 132% Share Price Gain?
finance.yahoo.com - September 10 at 12:35 PM
Can You Imagine How Jubilant Zai Lab's (NASDAQ:ZLAB) Shareholders Feel About Its 132% Share Price Gain?Can You Imagine How Jubilant Zai Lab's (NASDAQ:ZLAB) Shareholders Feel About Its 132% Share Price Gain?
finance.yahoo.com - September 10 at 12:35 PM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.